Maternal and Neonatal Outcomes After Respiratory Syncytial Virus Prefusion F Protein Vaccination During Pregnancy
This large observational study found no major safety concerns associated with RSVpreF vaccination during pregnancy. Further research, including international comparisons and evaluations of effectiveness relative to monoclonal antibodies against RSV, will be needed to fully characterize the benefit-risk balance of RSVpreF. Ongoing surveillance remains essential, particularly to monitor rare adverse events.
Authors
- Marie-Joëlle Jabagi (ORCID: https://orcid.org/0000-0002-7946-7759)
- A. Gabet (ORCID: https://orcid.org/0000-0003-1273-8988)
- Marion Bertrand (ORCID: https://orcid.org/0000-0002-4115-7093)
- Valérie Olié (ORCID: https://orcid.org/0000-0002-4837-1930)
- Epiphane Kolla (ORCID: https://orcid.org/0000-0003-4649-6833)
- Mahmoud Zureik (ORCID: https://orcid.org/0000-0002-8393-4217)
Institutions
- Twitter (United States) (US)
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris-Saclay (FR)
- National Confidential Enquiry into Patient Outcome and Death (GB)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (FR)
Publication Details
- Journal
- Obstetrics and Gynecology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1097/aog.0000000000006121
- Citations
- 4
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 5.42